General Surgery Unit, Misericordia and Dolce Hospital, Prato, Italy.
Surg Endosc. 2009 Oct;23(10):2214-20. doi: 10.1007/s00464-008-0301-6. Epub 2009 Jan 28.
Some scientific studies, with controversial results, have evaluated the efficacy in reducing pain of some different local anesthetic molecules, which were administered at different dosages and in different ways. The primary goal of this randomized, controlled, prospective study (Clinical Trials.gov ID NCT00599144) was to assess the effectiveness of 0.5% bupivacaine for pain control after video-laparoscopic cholecystectomy at its optimal dosage of 2 mg/kg infiltrated in the muscular fasciae of the trocars, or positioned in the gallbladder soaking a sheet of regenerated oxidized cellulose (Tabotamp).
A total of 45 patients underwent elective video-laparoscopic cholecystectomy. They were randomized in three groups each made of 15 patients: group A (bupivacaine-soaked Tabotamp positioned in the gallbladder bed), group B (bupivacaine infiltrated in the muscular fasciae of the trocars' seat), group C (control group, not using local anesthetic). Six and twenty-four hours after the intervention, the nature of the pain and its intensity were recorded with the use of a Visual Analogue Scale (VAS).
Six hours after the intervention, VAS average was 29.6 +/- 10.92 for group A, 25.86 +/- 16.06 for group B, and 36.13 +/- 16.62 for group C. At 24 h, we recorded 19.26 +/- 15.81, 18.53 +/- 12.3, and 20.46 +/- 20.08 for groups A, B, and C, respectively (p > 0.05). Comparing groups A and B between them and with the control group at 6 and 24 h, we deduced how only the first group showed a statistically significant advantage (p < 0.05) in reducing visceral and shoulder pain compared with the two other groups. Wound infiltration resulted in being statistically favorable in reducing parietal pain only when compared with Group A. For groups A and B, bupivacaine significantly reduced the use of postoperative pain killers.
Bupivacaine, either infiltrated in trocars' wounds or kept soaked in a regenerated oxidized cellulose sheet positioned in the gallbladder bed, although safe and not economically demanding, can increase postoperative comfort.
一些科学研究结果存在争议,评估了不同局部麻醉药物分子在不同剂量和不同方式下减轻疼痛的疗效。这项随机、对照、前瞻性研究(临床试验.gov 注册号 NCT00599144)的主要目的是评估 0.5%布比卡因在经皮腹腔镜胆囊切除术后的有效性,其最佳剂量为 2mg/kg 浸润于套管座的肌肉筋膜或放置在胆囊中浸泡再生氧化纤维素(Tabotamp)垫。
共 45 例择期行经皮腹腔镜胆囊切除术患者。他们被随机分为三组,每组 15 例:A 组(布比卡因浸泡的 Tabotamp 放置在胆囊床)、B 组(布比卡因浸润于套管座的肌肉筋膜)、C 组(对照组,不使用局部麻醉)。干预后 6 小时和 24 小时,使用视觉模拟评分(VAS)记录疼痛的性质和强度。
干预后 6 小时,A 组 VAS 平均为 29.6 +/- 10.92,B 组为 25.86 +/- 16.06,C 组为 36.13 +/- 16.62。24 小时时,我们记录到 A、B 和 C 组分别为 19.26 +/- 15.81、18.53 +/- 12.3 和 20.46 +/- 20.08(p > 0.05)。比较 A 组和 B 组之间以及与 C 组在 6 小时和 24 小时时,我们发现只有 A 组在减轻内脏和肩部疼痛方面具有统计学意义(p < 0.05)优于其他两组。与 A 组相比,套管伤口浸润仅在统计学上有利于减轻壁层疼痛。对于 A 组和 B 组,布比卡因可显著减少术后止痛药的使用。
布比卡因无论是浸润于套管伤口还是浸泡在胆囊床的再生氧化纤维素垫中,虽然安全且经济上要求不高,但可以提高术后舒适度。